带量采购中标药品左乙拉西坦片的临床应用评价

Abstract
Figure/Table
References (26)
Related Citation (3)

Download: PDF (576 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To preliminarily evaluate the clinical application consistency of the volume-based procurement of Jiyike of Levetiracetam (LEV) Tablets and Keppra from original LEV tablets based on prescription data. Methods Retrospective analysis was made on the prescription data of patients who used Jiyike and Keppra in outpatient department of Xuanwu Hospital, Capital Medical University before the implementation of the volume-based policy (March 2018 to January 2019) and after the implementation of the volume-based policy (March 2019 to January 2020). According to the 1∶1 nearest-neighbor propensity score matching method, the medication possession ratio, the continuous single drug use rate, the rate of continuous treatment for 3, 6 and 9 months, the abnormal upregulation rate of continuous treatment dose, and the continuous use rate after the first diagnosis were counted, and the drug replacement situation of the two was compared. The drug costs of Keppra and Jiyike after the implementation of the volume-based policy and the drug costs of LEV before and after the implementation of the volume-based policy were compared. Results There were no significant differences in the proportion of patients with ≥80%medication possession ratio between Jiyike group and Keppra group (P ＞ 0.05). The proportion of patients in Keppra group was higher than that in Jiyike group after 3, 6 and 9 months of continuous treatment (P ＜ 0.05). The abnormal upregulation rate of continuous treatment dose and continuous single drug use rate in Keppra group was significantly higher than that in Jiyike group (P ＜ 0.05). There was no significant difference in the continuous use rate between the two groups after the first diagnosis (P ＞ 0.05). There was no statistical significance in drug replacement between Jiyike group and Keppra group (P ＞ 0.05). The per capita annual drug cost in Jiyike group was lower than that in Keppra group, the difference was statistically significant (P ＜ 0.05). The per capita annual cost of LEV after the implementation of the volume-based policy was significantly lower than that before the implementation of the volume-based policy, with statistical significance (P ＜ 0.05). Conclusion The clinical application of Jiyike and Keppra is basically the same, and it can reduce the economic burden of patients to a large extent.

Key words： Levetiracetam Keppra Jiyike Volume-based procurement

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Li1
	2 DONG Xianzhe1 CUI Xiaohui1 LU Song2 LIU Wenna1 LI Lin1 YUE Xiaolin1 ZHANG Lan1

Cite this article:

YANG Li1,2 DONG Xianzhe1 CUI Xiaohui1 LU Song2 LIU Wenna1 LI Lin1 YUE Xiaolin1 ZHANG Lan1. Evaluation of clinical application of the acceptance drug Levetiracetam Tablets volume-based procurement[J]. 中国医药导报, 2021, 18(22): 41-45.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I22/41

[1] 中国抗癫痫协会.临床诊疗指南癫痫病分册（2015修订版）[M].北京：人民卫生出版社，2015：15-16.
[2] Kanner AM，Ashman E，Gloss D，et al. Practice guideline update summary：Efficacy and tolerability of the new antiepileptic drugs Ⅰ： Treatment of new-onset epilepsy： report of the American epilepsy Society and the Guideline development，Dissemination，and implementation Subcommittee of the American Academy of Neurology [J]. Epilepsy Curr，2018，18（4）：260-268.
[3] Chaari A，Mohamed AS，Abdelhakim K，et al. Levetiracetam versus Phenytoin for seizure Prophylaxis in brain injured Patients：a systematic review and meta-analysis[J]. Int J Clin Pharm，2017，39（5）：998-1003.
[4] Rhee SJ，Shin JW，Lee S，et al. Population Pharmacokinetics and dose-response relationship of levetiracetam in adult Patients with epilepsy [J]. Epilepsy Res，2017，132：8-14.
[5] Horváth L，Fekete K，Márton S，et al. Correlation between Prescribed daily dose，seizure freedom and defined daily dose in antiepileptic drug treatment [J]. Int J Clin Pharm，2017，39（2）：459-467.
[6] Nguyen ML，Sunderland B，Lim S，et al. The hidden magnitude of polypharmacy：using defined daily doses and maximum licensed daily doses to measure antipsychotic load [J]. Int J Clin Pharm，2019，41（6）：1642-1651.
[7] Wouters OJ，Kanavos PG，Mckee M. Comparing Generic Drug Markets in Europe and the United States： Prices，Volumes，and spending [J]. Milbank Q，2017，95（3）：554-601.
[8] Desai RJ，Sarpatwari A，Dejene S，et al. Comparative effectiveness of generic and brand-name medication use：A database study of US health insurance claims [J]. PloS Med，2019，16（3）：e1002763.
[9] Markoula S，Chatzistefanidis D，Gatzonis S，et al. Brand-to-generic levetiracetam switch in Patients with epilepsy in a routine clinical setting [J]. Seizure，2017，48：1-6.
[10] Vossler DG，Anderson GD，Bainbridge J. AES Position Statement on Generic Substitution of antiepileptic Drugs [J]. Epilepsy Curr，2016，16（3）：209-211.
[11] Trimboli M，Russo E，Mumoli L，et al. Brand-to-generic levetiracetam switching： a 4-year prospective observational real-life study [J]. Eur J Neurol，2018，25（4）：666-671.
[12] Gha-Hyun L，Dae SJ. Brand name to generic substitution of levetiracetam in patients with epilepsy [J]. Seizure，2018，60：127-131.
[13] Gagne JJ，Kesselheim AS，Choudhry NK，et al. Comparative effectiveness of generic versus brand-name antiepileptic medications [J]. Epilepsy Behav，2015，52（Pt A）：14-18.
[14] Olsson P，Reimers A，K?覿llén K. Quality of life after switching to generic levetiracetam-A prospective comparative study [J]. Epilepsy Behav，2019，96：169-174.
[15] Holtkamp M，Theodore WH. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy? [J]. Epilepsia, 2018，59（7）：1273-1281.
[16] LePorini C，De Sarro G，Russo E. Adherence to therapy and adverse drug reactions：is there a link? [J]. Expert Opin Drug Saf，2014，13 Suppl 1：S41-S55.
[17] Allard NL，MacLachlan JH，Dev A，et al. Adherence in chronic hepatitis B：associations between medication possession ratio and adverse viral outcomes [J]. BMC Gastroenterol，2020，20（1）：140.
[18] StolPe S，Kroes MA，Webb N，et al. A Systematic Review of Insulin Adherence Measures in Patients with Diabetes [J]. J Manag Care Spec Pharm，2016，22（11）：1224-1246.
[19] Sperber CM，Samarasinghe SR，Lomax GP. An upper and lower bound of the Medication Possession Ratio [J]. Patient Prefer Adherence，2017，11：1469-1478.
[20] Liu J，Xu R，Liu Z，et al. Factors influencing medication adherence after epilepsy surgery [J]. Epileptic Disord，2015，17（1）：47-51.
[21] Nakhutina L，Gonzalez JS，Margolis SA，et al. Adherence to antiepileptic drugs and beliefs about medication among Predominantly ethnic minority Patients with epilepsy [J]. Epilepsy Behav，2011，22（3）：584-586.
[22] 毛艳，汤继宏，柴建农，等.托吡酯治疗婴幼儿症状性癫痫的长期随访研究[J].中国基层医药，2018，25（7）：854-858，953.
[23] 张蕾，吴波，邓谦，等.托吡酯单药治疗儿童癫痫的长期随访调查[J].中国药剂学杂志，2020，18（3）：173-179.
[24] 王卫星，付淑芳，陈凤仪，等.不同类型抗癫痫药物对伴中央颞区棘波儿童良性癫痫注意网络损害及脑电图痫样放电的影响[J].疑难病杂志，2019，18（9）：904-909.
[25] 辛文佳，贺进波.传统和新型抗癫痫药物治疗新诊断癫痫患者的1年保留率比较[J].临床合理用药杂志，2021， 14（5）：73-75.
[26] 冯芹，张标，易兴阳，等.传统与新型抗癫痫药物在成人癫痫患者中的保留率及相关危险因素交互作用研究[J].中国现代医药杂志，2019，21（1）：11-15.